Skip to main content

Pipeline

Pre Clinical Phase 1 Phase 2 Phase 3

AV7909 (NuThrax™)

Anthrax Vaccine Candidate
(Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant)
*Phase 3 Study: First subject enrollment targeted for 2019

NuThrax™ (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant) is being studied for use as a third generation anthrax vaccine. This candidate consists of BioThrax® (Anthrax Vaccine Adsorbed) in combination with a novel immunostimulatory compound, CPG 7909.
 

Active Clinical Trials

  • No active clinical trials

Completed Clinical Trials

      2019*

FLU-IGIV

Seasonal Influenza Therapeutic Candidate
Hyperimmune Platform
**Phase 3 Study: First subject enrollment targeted for 2019
      2019**

VLA1601

Zika Virus Candidate
Injectable Purified, Inactivated Zika Virus Vaccine
   

ZIKV-IG

Zika Therapeutic Candidate
Hyperimmune Platform
**Phase 1 Study: First subject enrollment targeted for 2018
  2018**

UNI-FLU

Universal Influenza Vaccine Candidate
Injectable Nanoparticle Universal Influenza Vaccine
 

EBX-205

Broad-Spectrum Antibiotic Candidate
Oral Topoisomerase Inhibitor
 

GC-072

Burkholderia Therapeutic Candidate
Oral Topoisomerase Inhibitor
 

FILOV

Pan-filovirus Therapeutic Candidate (Ebola, Marburg, Sudan)
Hyperimmune Platform, Monoclonal Antibody
 

EBI-001

Iminosugar Antiviral Candidate
Oral Glucosidase Inhibitor
 

Clinical Trials Resources

To learn more about Clinical Trials, visit the websites below. These sites are maintained by ClinicalTrials.gov, a web-based resource that provides patients, their family members, health care professionals, researchers, and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions. ClinicalTrials.gov is maintained by the National Library of Medicine at the National Institutes of Health.